Factor XIII contrasts the effects of metalloproteinases in human dermal fibroblast cultured cells

Vascular and Endovascular Surgery

Volumn 38, Issue 5, 2004, Pages 431-438

  Zamboni, Paolo ^a,b   De Mattei, Monica ^a,b   Ongaro, Alessia ^a,b   Fogato, Luisella ^a,b   Carandina, Sergio ^a,b   De Palma, Massimiliano ^a,b   Tognazzo, Silvia ^a,b   Scapoli, Gian Luigi ^a,b   Serino, Maria Luisa ^a,b   Caruso, Angelo ^a,b   Liboni, Alberto ^a,b   Gemmati, Donato ^a,b  

^a University of Ferrara ^*

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; COLLAGENASE; METALLOPROTEINASE; TRYPAN BLUE;

ARTICLE; BIOLOGICAL MONITORING; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; EVALUATION; EXTRACELLULAR MATRIX; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEG ULCER; PATHOGENESIS; SKIN CELL; ULCER HEALING;

CELLS, CULTURED; CLOSTRIDIUM HISTOLYTICUM; FACTOR XIII; FIBROBLASTS; HUMANS; MATRIX METALLOPROTEINASES; MICROBIAL COLLAGENASE; MIDDLE AGED;

EID: 4744364274     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/153857440403800506     Document Type: Article

References (29)

1. Birkedal-Hansen H: Proteolytic remodelling of extracellular matrix. Cur Opin Cell Biol 7:728-735, 1995.
2. Kumar D, Gupta SP: A quantitative structure-activity relationship study on some matrix metalloproteinase and collagenase inhibitors. Bioorg Med Chem 11:421-426, 2003.
3. Herouy Y, Mellios P, Banderir E, et al: Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression. J Dermatol Sci 25:198-205, 2001.
4. Herouy Y, May AE, Pornschelegel G, et al: Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: Implications for venous ulcer formation. J Invest Dermatol 111:822-827, 1998.
5. McDonagh J, Fukue H: Determinants of substrate specificity for factor XIII. Thromb Hemost 22:369-376, 1996.
6. Muszbek L, Yee VC, Hevessy Z: Blood coagulation factor XIII: Structure and function. Thromb Res 94:271-305, 1999.
7. Tamaki T, Aoki N: Cross-linking of alpha 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta 661:280-286, 1981.
8. Keski-Oja J, Mosher DF, Vaheri A: Cross-linking of a major fibroblast surface-associated glycoprotein (fibronectin) catalyzed by blood coagulation factor XIII. Cell 9:29-35, 1976.
9. Barry EL, Mosher DF: Factor XIIIa-mediated cross-linking of fibronectin in fibroblast cell layers. Cross-linking of cellular and plasma fibronectin and of amino-terminal fibronectin fragments. J Biol Chem 264:4179-4185, 1989.
10. Barry EL, Mosher DF: Factor XIII cross-linking of fibronectin at cellular matrix assembly sites. J Biol Chem 263:10464-10469, 1988.
11. Mosher DF, Vaheri A: Binding and degradation of alpha 2-macroglobulin by cultured fibroblasts. Biochim Biophys Acta 627:113-122, 1980.
12. Ueyama M, Urayama T: The role of factor XIII in fibroblast proliferation. Jpn J Exp Med 48:135-142, 1978.
13. Bruhn HD, Pohl J: Growth regulation of fibroblasts by thrombin, factor XIII and fibronectin. Klin Wochenschr 59:145-146, 1981.
14. Jung CM, Matsushita O, Katayama S, et al: Identification of metal ligands in the Clostridium histolyticum ColH collagenase. J Bacteriol 181:2816-2822, 1999.
15. Matsushita O, Okabe A: Clostridial hydrolytic enzymes degrading extracellular components. Toxicon 39:1769-1780, 2001.
16. Herouy Y, Hellstern MO, Vanscheidt W, et al: Factor XIII-mediated inhibition of fibrinolysis and venous leg ulcers. Lancet 355:1970-1971, 2000.
17. Wozniak G, Noll T, Brunner U, et al: Topical treatment of venous ulcer with fibrin stabilizing factor: Experimental investigation of effects on vascular permeability. Vasa 28:160-163, 1999.
18. Peschen M, Thimm C, Weyl A, et al: Possible role of coagulation factor XIII in the pathogenesis of venous leg ulcers. Vasa 27:89-93, 1998.
19. Vanscheidt W, Hasler K, Wokalek H, et al: Factor XIII-deficiency in the blood of venous leg ulcer patients. Acta Derm Venereol 71:55-57, 1991.
20. Paye M, Nusgens BV, Lapiere CM: Factor XIII of blood coagulation modulates collagen biosynthesis by fibroblasts in vitro. Haemostasis 19:274-283, 1989.
21. Corbett SA, Lee L, Wilson CL, et al: Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix. J Biol Chem 272:24999-25005, 1997.
22. Sane DC, Moser TL, Pippen AM, et al: Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Commun 157:115-120, 1988.
23. Brown LF, Lanir N, McDonagh J, et al: Fibroblast migration in fibrin gel matrices. Am J Pathol 142:273-283, 1993.
24. Norgauer J, Mockenhaupt M, Herouy Y: Blood coagulation factor XIII and wound healing in leg ulcers. Biochem Prog 14:67-70, 2001.
25. Mendez MV, Raffetto JD, Phillips T, et al: The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: A potential mechanism for senescence in venous ulcers. J Vasc Surg 30:734-743, 1999.
26. Raffetto JD, Mendez MV, Marien BJ, et al: Changes in cellular motility and cytoskeletal actin in fibroblasts from patients with chronic venous insufficiency and in neonatal fibroblasts in the presence of chronic wound fluid. J Vasc Surg 33:1233-1241, 2001.
27. Paye M, Nusgens B, Lapiere CM: Factor XIII of blood coagulation decreases the susceptibility of collagen precursors to proteolysis. Biochim Biophys Acta 1073:437-441, 1991.
28. Collen D: Role of the plasminogen system in fibrin-homeostasis and tissue remodeling. Hematol (Am Soc Hematol Educ Program) 1:1-9, 2001.
29. Stacey MC, Burnand KG, Mahmoud-Alexandroni M, et al: Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers. Br J Surg 80:596-599, 1993.